The approval adds an AI lung sound analysis algorithm to TytoCare's Home Smart Clinic solutions to expand acute care and chronic condition management


The Tyto Insights for Wheeze Detection algorithm by TytoCare supports assessment of lung sound data. (Credit: Robina Weermeijer on Unsplash)

Virtual care company TytoCare has received the US Food and Drug Administration (FDA) clearance for its Tyto Insights for Wheeze Detection to enhance diagnostic accuracy in the home setting.

The latest wheeze detection algorithm is said to broaden the smart diagnostic capabilities of the firm’s current artificial intelligence (AI)-driven Tyto Insights.

TytoCare said that the algorithm also covers the currently experienced quality gaps with conventional telemedicine, and removes difficulties imposed by the ongoing scarcity of healthcare personnel.

The US-based virtual care company has designed the algorithm to support lung sound data assessment in adults and children, two years of age and older. It enables doctors to precisely diagnose respiratory diseases remotely.

The AI-powered decision support software enables the automatic analyses of the lung sounds captured by TytoCare’s FDA-cleared portable remote exam device’s stethoscope to detect wheezing.

The analysis is supported by TytoCare’s own database of lung sounds.

Tyto Insights for Wheeze Detection alerts a clinician whenever a remote lung exam using TytoCare is performed if a certain abnormal lung sound indicative of wheezing is suspected.

TytoCare CEO and co-founder Dedi Gilad said: “Our Tyto Insight capabilities, including our wheeze detection algorithm, furthers our goal of enhancing the virtual care experience for all patients, clinicians, providers, and health plans – not just by increasing the quality of care and expanding our chronic care management capabilities, but also by further assisting clinicians and specialists to make informed and accurate diagnoses remotely.

“At TytoCare, we have the world’s largest database of lung and heart sounds, as well as related symptoms and vital signs, and we will continue to leverage it to provide superb quality of care for families worldwide.”

The approval adds the AI lung sound analysis algorithm to TytoCare’s Home Smart Clinic solutions to expand acute care and long-term care for chronic disorders.

The Tyto Insights for Wheeze Detection has already secured the CE Mark for use in Europe.